Ascentage Pharma Group Internat Share Price & Technical Analysis
AAPG · $21.01 (+2.14%)
Healthcare / Biotechnology
$21.01
+2.14%
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibito…
Price chart
Seasonality
May has 0 positive and 2 negative years (last 2 years shown)
-8% return in May, -2% avg return in past 3 year May month.
-24% return in 2026, 51% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -8% | 3% | 3% | -13% | -8% | – | – | – | – | – | – | – | -24% |
| 25 | 3% | 7% | 13% | 8% | -2% | 60% | -5% | 15% | -7% | -16% | -5% | -19% | 51% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.96B
P/E ratio
—
52W high
$48.45
52W low
$18.56
Volume
8,252
Beta
0.72
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Ascentage Pharma Group Internat share price today?
- Ascentage Pharma Group Internat (AAPG) last traded around $21.01 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does AAPG have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for AAPG. Download the app for real-time alerts.
- How can I analyze Ascentage Pharma Group Internat stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.